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Expanded Abstract 
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Background 
Corticosteroids have been used to treat head injuries for 
more than 30 years. In 1997, findings of a systematic review 
suggested that these drugs reduce risk of death by 1–2%. 
The CRASH trial—a multicentre international 
collaboration—aimed to confirm or refute such an effect by 
recruiting 20,000 patients. In May 2004, the data monitoring 
committee disclosed the unmasked results to the steering 
committee, which stopped recruitment. 
Methods 
10,008 adults with head injury and a Glasgow coma score 
(GCS) of 14 or less within 8 hours of injury were randomly 
allocated 48 hour infusion of corticosteroids 
(methylprednisolone) or placebo. Primary outcomes were 
death within 2-weeks of injury and death or disability at 6-
months. Prespecified subgroup analyses were based on 
injury severity (GCS) at randomisation and on time from 
injury to randomisation. Analysis was by intention to treat. 
Effects on outcomes within 2 weeks of randomisation were 
presented in this report. 
 
 
Findings 
Compared with placebo, the risk of death from all causes 
within 2 weeks was higher in the group allocated 
corticosteroids (1052 [21.1%] vs. 893 [17.9%] deaths; 
relative risk 1.18 [95% CI 1.09–1.27]; P=0.0001). The 
relative increase in deaths due to corticosteroids did not 
differ by injury severity (p=0.22) or time since injury 
(p=0.05). 
Conclusion 
These results show there is no reduction in mortality with 
methylprednisolone in the 2 weeks after head injury. The 
cause of the rise in risk of death within 2 weeks is unclear. 
Commentary 
Head injury is a major cause of morbidity and mortality 
worldwide. Corticosteroids (steroids) have been used to 
treat head injury for more than 30 years after early reports 
of their beneficial effects in patients with cerebral edema 
due to brain tumors and surgery [2]. By reducing intracranial 
edema and pressure, it was believed that steroids would 
improve blood flow, reduce the occurrence of herniation, 
and, therefore, lead to improved clinical outcomes. 
Enthusiasm regarding their use in head injury was 
bolstered, in part, by improvements seen with their use in 
patients with acute spinal cord injuries [3,4]. Studies 
examining steroid treatment in acute head injury have 
provided mixed results, though a recent systematic review 
suggested a 1-2% lower risk of death for patients treated 
with corticosteroids [5]. 
Smashing into this practice is the CRASH (Corticosteroid 
Randomization After Significant Head injury) trial, a 
randomized placebo-controlled multicenter trial of early 
steroids in 10,008 adults with head injury. In this study, 
head injured subjects with a Glasgow coma scale of 14 or Critical Care   October 2005 Vol 9 No 5    Czekajlo and Milbrandt 
less received either a loading dose of 2 grams of 
methylprednisolone followed by a 0.4 gram/hr infusion for 
48 hours or matching placebo within 8 hours of injury. 
Groups were well balanced at baseline with respect to 
clinically relevant variables. The CRASH investigators 
initially planned to enroll 20,000 subjects. The trial was 
stopped early when it was discovered at interim analysis 
that steroid-treated subjects had significantly higher all-
cause 2-week mortality (21.1% vs. 17.9%, p=0.0001). 
Subsequent follow-up demonstrated that 6-month mortality 
was also higher in steroid treated subjects (25.7% vs. 
22.3%, p=0.0001), with a trend toward increases in the 
combined endpoint of death or severe disability (38.1% vs. 
36.3%, p=0.08) [6]. In neither report did the results differ by 
injury severity or time since injury. 
This well-done study was remarkable for many reasons. 
The sheer size of this trial is staggering, especially 
considering the logistics of conducting a blinded, placebo-
controlled trial in 239 hospitals across 49 countries. It is also 
impressive that subjects were enrolled and randomized 
within eight hours of injury. That the investigators achieved 
96.7% 6-month follow-up certainly raises the bar for other 
long-term outcomes studies of critically ill patients. 
A few limitations of this study deserve consideration. Few 
details regarding patient management both before and after 
randomization were given. No centers from North America 
were included in this trial. It is difficult to imagine, however, 
that practice patterns differ sufficiently that the results would 
have differed were the study conducted in North America. 
The authors did not report what percentage of subjects had 
concomitant spinal cord injury, leaving unanswered the 
question of whether patients with combined head and spinal 
cord injury should receive steroids. 
The key question that remains is why corticosteroid-treated 
subjects fared worse. Complications, such as seizures, 
gastrointestinal bleeding, and infection, were similar in both 
groups. The authors note that they remain unsure of the 
mechanism of increased mortality with steroids. The lack of 
an identifiable etiology, however, does not diminish the 
validity or importance of the results. 
Recommendation 
Based on the results of the CRASH trial, steroids should not 
be used routinely in the treatment of acute traumatic head 
injury. 
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